By
Drug Target Review2023-12-12T12:00:53
The new small molecule targets the glutamate system, reducing MS-like symptoms and repairing damaged myelin in two different animal models.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2024-01-26T13:22:42
Sponsored by bit.bio
2025-09-24T14:00:00
Sponsored by Eurofins Discovery
2026-06-02T15:00:00 2026-06-02T16:00:00
Sponsored by Danaher Life Sciences
2024-02-06T08:57:06
Sponsored by bit.bio
2026-06-24T13:00:00 2026-06-24T14:00:00
Sponsored by HUB Organoids
2023-05-30T13:51:56
Sponsored by BPS Bioscience
Site powered by Webvision Cloud